Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER
Publication
, Conference
Jaffe, GJ; Koh, AHC; Ogura, Y; Weichselberger, A; Holz, FG; Dugel, PU
Published in: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
July 1, 2018
Duke Scholars
Published In
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
EISSN
1552-5783
ISSN
0146-0404
Publication Date
July 1, 2018
Volume
59
Issue
9
Location
Honolulu, HI
Publisher
ASSOC RESEARCH VISION OPHTHALMOLOGY INC
Conference Name
Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
Related Subject Headings
- Ophthalmology & Optometry
- 3212 Ophthalmology and optometry
- 11 Medical and Health Sciences
- 06 Biological Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Jaffe, G. J., Koh, A. H. C., Ogura, Y., Weichselberger, A., Holz, F. G., & Dugel, P. U. (2018). Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (Vol. 59). Honolulu, HI: ASSOC RESEARCH VISION OPHTHALMOLOGY INC.
Jaffe, Glenn J., Adrian H. C. Koh, Yuichiro Ogura, Andreas Weichselberger, Frank G. Holz, and Pravin U. Dugel. “Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER.” In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, Vol. 59. ASSOC RESEARCH VISION OPHTHALMOLOGY INC, 2018.
Jaffe GJ, Koh AHC, Ogura Y, Weichselberger A, Holz FG, Dugel PU. Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER. In: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. ASSOC RESEARCH VISION OPHTHALMOLOGY INC; 2018.
Jaffe, Glenn J., et al. “Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER.” INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 59, no. 9, ASSOC RESEARCH VISION OPHTHALMOLOGY INC, 2018.
Jaffe GJ, Koh AHC, Ogura Y, Weichselberger A, Holz FG, Dugel PU. Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. ASSOC RESEARCH VISION OPHTHALMOLOGY INC; 2018.
Published In
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
EISSN
1552-5783
ISSN
0146-0404
Publication Date
July 1, 2018
Volume
59
Issue
9
Location
Honolulu, HI
Publisher
ASSOC RESEARCH VISION OPHTHALMOLOGY INC
Conference Name
Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
Related Subject Headings
- Ophthalmology & Optometry
- 3212 Ophthalmology and optometry
- 11 Medical and Health Sciences
- 06 Biological Sciences